Abivax announced on September 23, 2025, the acceptance of a late-breaking abstract for presentation at The United European Gastroenterology Congress, taking place from October 4-7, 2025, in Berlin, Germany. The abstract will detail findings for its lead drug candidate, obefazimod, from the ABTECT Phase 3 induction trials for moderately to severely active ulcerative colitis (UC).
Fabio Cataldi, Chief Medical Officer of Abivax, stated that the acceptance of this late-breaking abstract underscores obefazimod's potential as a new therapeutic option for UC patients. The company is eager to share the detailed findings, which are expected to demonstrate obefazimod’s efficacy in a diverse patient population.
This includes patients who have not responded adequately to other advanced therapies. The presentation at a major European gastroenterology congress will provide further scientific validation and visibility for obefazimod's clinical profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.